Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prosena Therapeutics

- PMLiVE

GSK eyes first-line use for leukaemia drug Arzerra

Positive phase III trial results back regulatory filings for earlier use

- PMLiVE

FDA clears two GSK melanoma drugs

Tafinlar and Mekinist approved in the US along with companion diagnostic

- PMLiVE

GSK boost vaccines capabilities with €250m Okairos purchase

Acquires novel platform technology and several early stage assets

- PMLiVE

GSK awarded $200m by US government for antibiotic research

Follows state-supported schemes in Europe to combat resistance to antibiotics

GSK partners with Save the Children to tackle child mortality in Africa

Firm will develop and distribute medicines in some of the world’s poorest countries 

- PMLiVE

Elan buys into GSK-partnered Theravance programmes for $1bn

Takes a royalty interest in four respiratory drugs

- PMLiVE

GSK wins US approval for Seretide successor Breo Ellipta

FDA gives green light to COPD combination

- PMLiVE

Bringing trial data out of the shadows

Transparency of clinical trial data has become a hotly disputed topic recently, how the industry at large will respond is still not clear, but as the noise grows louder, reputations...

Merck & Co and GSK offer discounted cervical vaccines to developing nations

Pharma companies team up with GAVI Alliance to provide Cervarix and Gardasil

- PMLiVE

GSK to set up online system for trial data requests

Pharma company fleshes out transparency plans

- PMLiVE

GSK submits COPD drug in US and EU

Umeclidinium bromide intended as monotherapy for lung condition

- PMLiVE

GSK and Impax end Parkinson’s collaboration

Regulatory delays for IPX066 lead to split

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links